The Real World Evidence Co-Investment Program places MoreBetter’s research platform, study design and analysis behind longitudinal, patient-reported outcomes studies; applications are open now
PHILADELPHIA, Nov. 10, 2026 /PRNewswire/ — MoreBetter, Ltd. today launched the MoreBetter Real World Evidence Co-Investment Program (the RWE Co-Investment Program), under which MoreBetter will co-invest its research platform, study design and analysis in longitudinal studies of patient-reported outcomes for longevity, peptide, and psychedelic and ketamine therapies. The RWE Co-Investment Program is open to the providers, compounding pharmacies, clinics and brands that deliver these therapies. MoreBetter has committed capacity to co-invest in up to 10 studies over the program’s first 12 months, and applications are open now.
Longevity, peptide, and psychedelic and ketamine therapies are in wide use, but there is little longitudinal, patient-level evidence on them. Many are cash-pay, compounded, prescribed off-label or regulated state by state, which places them outside the settings where conventional trials take place, and products and regimens vary widely. Regulators and states are moving ahead. In October, the U.S. Department of Health and Human Services issued an interim enforcement discretion policy that allows pharmacies to compound six peptides, including BPC-157, under specified conditions, following a July vote by an FDA advisory committee. The peptides remain unapproved, and the policy applies only until FDA completes rulemaking. Oregon and Colorado operate state-regulated psilocybin programs, and Texas has designated state funds for ibogaine research.
Through the RWE Co-Investment Program, MoreBetter designs each study, including the instruments, assessment schedule, adverse event capture and analysis plan, and runs it on Penzai, MoreBetter’s 21 CFR Part 11-compliant research platform. Participants complete short questionnaires on a schedule that can be as frequent as daily, prompted by text message, a design intended to support adherence and ongoing engagement. They are followed over time as they use a partner’s product and regimen in everyday life. Every study uses the same validated instruments, so results can be compared across products and providers. Partners receive longitudinal patient-reported outcome and adverse event data, with analysis by MoreBetter, that they can bring to their own clinical, sponsor, investor and regulatory conversations. MoreBetter’s contribution is scaled to each study.
“Longevity, peptide and psychedelic therapies are in daily use, yet very little is measured about what patients experience over time. The RWE Co-Investment Program puts MoreBetter’s research infrastructure behind that question, so providers and sponsors can answer it with data.” said Kevin Provost, Chief Executive Officer of MoreBetter.
MoreBetter’s research has produced 18 peer-reviewed publications with 12 university research partners, and the company’s data has been provided to the U.S. Food and Drug Administration under contract. MoreBetter built its methods in cannabinoid research, an evidence environment defined by federal restrictions, wide product variation and real-world use. Longevity, peptide, and psychedelic and ketamine therapies share those conditions.
Studies in the RWE Co-Investment Program use validated instruments, protocols designed for review by an institutional review board, and de-identification and data governance designed for regulated research.
Using a common outcome standard and in collaboration with MoreBetter’s university research partners, MoreBetter intends to publish aggregate, de-identified, category-level findings where partner agreements allow, so that the findings benefit each category as a whole.
MoreBetter is also working with data partners to enable HIPAA-compliant linkage of patient-reported outcomes with electronic health record and claims data. Where available, that linkage would allow studies to connect patient-reported outcomes with clinical records while protecting personal privacy.
Partners are selected on three criteria: a defined product that participants can legally access, a defined use regimen, and a research question suited to longitudinal patient-reported outcomes.
Applications for the RWE Co-Investment Program are open at morebetter.ltd. Partners are reviewed on a rolling basis for studies launching beginning in the first quarter of 2027. Longevity and healthspan clinics, compounding pharmacies, telehealth providers, ketamine and psychedelic therapy providers, brands and research sponsors are encouraged to apply. Universities, health departments and state agencies can reach MoreBetter at kevin@morebetter.ltd.
Regulatory status varies by therapy and is changing. Ketamine is a Schedule III controlled substance, FDA-approved as an anesthetic and used off-label in psychiatric care; FDA has warned that compounded ketamine used for psychiatric conditions outside a monitored setting carries safety risks. Psilocybin and ibogaine are Schedule I controlled substances federally. BPC-157 and the other peptides covered by the HHS policy are not FDA-approved, and compounded products made from them remain unapproved drugs. MoreBetter’s studies are research programs; MoreBetter does not supply, prescribe or administer any product.
This is real-world, patient-reported outcomes research. It is not a clinical trial. MoreBetter makes no claim that any product or therapy treats, prevents or cures any condition, or that any product or therapy is safe or effective.
About MoreBetter
MoreBetter, Ltd., founded in 2016, is a clinical research infrastructure company that designs and runs prospective, patient-reported outcome studies and real-world evidence programs for academic, pharmaceutical and industry sponsors. Its platform supports IRB-reviewed protocols, validated clinical instruments and data governance built for regulated research. Working with 12 university research partners, state and federal regulators, MoreBetter has produced 18 peer-reviewed publications. MoreBetter generates data, not claims. Learn more at morebetter.ltd.
Media Contact
Kevin Provost, Chief Executive Officer, MoreBetter | kevin@morebetter.ltd | 248.808.8120 | morebetter.ltd
View original content:https://www.prnewswire.com/news-releases/morebetter-launches-co-investment-program-for-longevity-peptide-and-psychedelic-therapies-302935599.html
SOURCE MoreBetter
